Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: BioDelivery Sciences International, Inc., a specialty pharmaceutical company, develops and commercializes therapeutics in the areas of pain management and oncology supportive care. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, bi-layered erodible polymer film for application to the buccal mucosa. Its products include ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in patients with cancer; and BEMA Buprenorphine that is in Phase III trial for the treatment of chronic pain in a mixed opioid naïve and opioid experienced population. The company is also involved in the development of BUNAVAIL for the maintenance treatment of opioid dependence; and Clonidine Topical Gel for the treatment of painful diabetic neuropathy. It has a licensing and development agreement with Endo Pharmaceuticals, Inc. to develop and commercialize BEMA Buprenorphine; and license agreement with Arcion Therapeutics.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-0.35||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-5.98%||Sales Growth - Q/Q||412.53%||P/E||-6.57|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-70.05%||ROE||-115.89%||ROI||-109.33%|
|Current Ratio||2.42||Quick Ratio||2.34||Long Term Debt/Equity||0.05||Debt Ratio||0.59|
|Gross Margin||82.95%||Operating Margin||-150.93%||Net Profit Margin||-184.52%||Dividend Payout Ratio|
|Cash From Financing Activities||-1.86 M||Cash From Investing Activities||-140 K||Cash From Operating Activities||-5 M||Gross Profit||11.93 M|
|Net Profit||-8.19 M||Operating Profit||-7.8 M||Total Assets||82.47 M||Total Current Assets||71.74 M|
|Total Current Liabilities||29.59 M||Total Debt||10.26 M||Total Liabilities||32.62 M||Total Revenue||13.05 M|
|High 52 week||5.3||Low 52 week||1.7||Last close||4.57||Last change||-0.44%|
|RSI||36.36||Average true range||0.19||Beta||0.69||Volume||448.88 K|
|Simple moving average 20 days||-5.36%||Simple moving average 50 days||-6.96%||Simple moving average 200 days||16.74%|
|Performance Week||-7.86%||Performance Month||-2.35%||Performance Quart||-1.3%||Performance Half||26.24%|
|Performance Year||134.36%||Performance Year-to-date||23.51%||Volatility daily||1.98%||Volatility weekly||4.43%|
|Volatility monthly||9.07%||Volatility yearly||31.42%||Relative Volume||117.27%||Average Volume||1.09 M|
|New High||New Low|
2019-06-24 08:00:00 | BioDelivery Sciences Expands Upon Report from Pain Management Task Force
2019-06-20 09:18:01 | 5 Top Rate-Sensitive Stocks to Buy Amid Fed's Rate Cut Hints
2019-06-20 08:00:00 | BioDelivery Sciences Named to the Russell 3000® Index
2019-06-19 20:43:15 | Here’s What Hedge Funds Think About BioDelivery Sciences International, Inc. BDSI
2019-06-05 09:30:01 | Why Is BioDelivery BDSI Down 12.3% Since Last Earnings Report?
2019-05-31 08:33:48 | Triangle company uses new financial strength to lock down favorable loan
2019-05-29 16:10:00 | BioDelivery Sciences Announces Upcoming Investor Conference Presentations
2019-05-28 16:10:00 | BioDelivery Sciences Strengthens Financial Position with Debt Refinancing
2019-05-22 07:21:11 | 5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon
2019-05-21 09:00:01 | All You Need to Know About BioDelivery BDSI Rating Upgrade to Buy
2019-05-07 09:40:01 | BioDelivery BDSI Stock Up on Q1 Earnings and Sales Beat
2019-05-07 07:58:41 | Edited Transcript of BDSI earnings conference call or presentation 6-May-19 8:30pm GMT
2019-05-06 22:03:33 | BioDelivery Sciences International, Inc. BDSI Q1 2019 Earnings Call Transcript
2019-05-06 18:45:10 | BioDelivery Sciences International BDSI Reports Q1 Loss, Tops Revenue Estimates
2019-05-06 17:40:42 | BioDelivery: 1Q Earnings Snapshot
2019-05-02 10:11:02 | What's in Store for BioDelivery BDSI This Earnings Season?
2019-04-25 16:30:00 | BioDelivery Sciences to Report First Quarter 2019 Financial Results
2019-04-17 09:00:01 | What Makes BioDelivery BDSI a New Buy Stock
2019-04-13 09:30:01 | BioDelivery BDSI Up 7.8% Since Last Earnings Report: Can It Continue?
2019-04-11 10:45:25 | BDSI expects $50 million in latest public offering
2019-04-11 09:34:01 | BioDelivery BDSI Buys US Rights to Pain Drug for $30M
2019-04-11 07:25:27 | BDSI announces public offering after paying $30M for drug rights
2019-04-10 16:06:08 | BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
2019-03-22 18:24:00 | Lifshitz & Miller LLP Announces Investigation of Alta Mesa Resources, Inc., American Renal Associates LLC, Belden, Inc., BioDelivery Sciences, Inc., Blue Valley Bank Corp., Bridgepoint Education, Inc., and Care.com, Inc.
2019-03-21 17:45:09 | BioDelivery Sciences International BDSI Gains But Lags Market: What You Should Know
2019-03-19 14:26:06 | Catalyst CPRX Reports Wider Q4 Loss, Focuses on Firdapse
2019-03-18 18:44:10 | Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
2019-03-15 10:23:02 | BioDelivery BDSI Q4 Earnings In Line, Sales Beat, Stock Up
2019-03-14 23:51:23 | Edited Transcript of BDSI earnings conference call or presentation 14-Mar-19 8:30pm GMT
2019-03-14 20:20:00 | Biodelivery Sciences International Inc BDSI Q4 2018 Earnings Conference Call Transcript
2019-03-14 19:45:29 | BioDelivery: 4Q Earnings Snapshot
2019-03-14 16:05:00 | BioDelivery Sciences Reports Strong 2018 Results and 2019 Expectations
2019-03-14 14:30:00 | BioDelivery Sciences International, Inc. to Host Earnings Call
2019-03-13 12:50:04 | Aerie AERI Receives FDA Nod for Rocklatan to Treat Glaucoma
2019-03-12 09:59:01 | Alnylam Files Application for Hypertension Candidate in UK
2019-03-11 10:35:02 | AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study
2019-03-11 10:00:02 | What Makes BioDelivery Sciences International BDSI a Strong Momentum Stock: Buy Now?
2019-03-11 09:56:01 | Will the Decade-Old Bull Market Momentum Last? 5 Picks
2019-03-05 16:36:09 | What's in Store for BioSpecifics BSTC This Earnings Season?